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    Human metapneumovirus (hMPV) is a recently discovered paramyxovirus known to cause 
respiratory tract infections primarily in children.  This previously unknown pathogen remained 
undetected for years due to very slow replication in vitro and an inconsistent CPE.  More 
recently, detection of hMPV by means of quantitative molecular techniques has proved to be 
more effective than culture methods.  In this study we describe the development of a quantitative 
real time RT-PCR assay targeting the hMPV nucleoprotein (N) gene.  This assay is compared to 
a real time nucleic acid sequence based amplification (NASBA) test, developed by bioMérieux, 
using control material from hMPV strains Can97-83 and Can98-75 representative of the two 
main lineages A and B, respectively.  Using control material the real time RT-PCR, designed to 
detect all four sublineages of hMPV, can detect as low as 50 and 100 copies of viral RNA from 
the A and B lineages respectively.   The real time NASBA assay can also detect 50 copies of 
viral RNA from the A strain but only detects 1000 copies of strain B viral RNA.  In this study, 
hMPV has been detected in both immunosuppressed lung transplant recipients (2.14%) and 
children with respiratory symptoms (1.83%).  This research is of major public health significance 
due to the amount of respiratory infections that are going undiagnosed or being treated with 
unnecessary antibiotics.  It is important for our physicians to not only know that hMPV is present 
in our community but also to be able to detect and treat it appropriately.  This study reports the 
first evidence of hMPV in the Pittsburgh area and demonstrates the importance of this virus as a 
critical player among respiratory pathogens in both immunosuppressed lung transplant recipients 
 iv
and children.  In conclusion, we have successfully developed a real time RT-PCR assay targeting 
the hMPV N gene.  Using this assay along with the real time NASBA assay developed by 
bioMérieux, we have detected hMPV infections in lung transplant recipients in a year long study. 
Using the real time RT-PCR assay alone hMPV has also been detected in children suspected of 
respiratory infection during the early winter season.   
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1. Introduction 
    Human metapneumovirus (hMPV) was first described in 2001 as a novel paramyxovirus 
isolated from the respiratory tract of children in the Netherlands (1).   
Since its initial description, hMPV has been reported all over the world (2-9) and detected in 
patients ranging in age from 2 months to 87 years old, though children appear to be the most 
affected population (10).  Retrospective studies have shown that hMPV is responsible for 4.5-
17% of acute respiratory tract infections (ARTIs) in children, making it the second most 
prevalent respiratory virus in this age group following only respiratory syncytial virus (RSV) 
(3,4,11,12).  In addition, 6.2-39% of ARTIs negative for other common respiratory viruses are 
positive for hMPV (5-7,13-16) and 1.2-4.1% of asymptomatic individuals are positive for 
hMPV, indicating the possibility of unapparent infections (12,16).  Population based studies 
looking at the serostatus of individuals show that the virus has been circulating in the population 
since at least 1958 and nearly all children are seropositive by the age of five (1).    
    Studies have closely associated hMPV and RSV infections due to their ability to affect the 
same patient population during the late winter season (Jan- Apr).  ARTIs of viral origin are the 
number one cause of pediatric hospitalizations during the winter season.  RSV is responsible for 
the majority of ARTIs, followed by hMPV, then parainfluenza virus (PIV)-3 with incidence rates 
of 20%, 6.2%, and 3.1% respectively  (15).  Like RSV, hMPV causes occasional upper 
respiratory tract infections, although lower respiratory tract infections resulting in bronchiolitis, 
pneumonitis, bronchitis, pneumonia, and asthma are more common.  Bronchiolitis is the most 
common (24-86%) of these diagnoses from hMPV infections (4-6,11,16,17).  The clinical signs 
and symptoms for RSV and hMPV in children are indistinguishable,  however RSV infects at an 
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earlier age than hMPV as evidenced by a seroprevalence of 48% and 11% respectively in 
patients less than 1 year old (18).  hMPV signs and symptoms are consistent with those of RSV 
including dyspnea (83.3-95%), fever (52-91.7%), cough (69-90%), rhinorrhea (69-77%), 
weezing (50-52%), hypoxemia (31%) and croup (18%) (5,11,12,16).  Hoarseness occurs in 91% 
of hMPV infected individuals, making it the only symptom that is significantly different from 
RSV (42%) (12).   
    hMPV is known to infect primarily children, but has been seen in all ages of people 
throughout many geographical locations.  Critical hMPV cases have been reported in elderly and 
immunosuppressed individuals, though there have yet to be prevalence studies in many of these 
various patient populations.  Solid organ transplant recipients are extremely immunosuppressed 
leaving them susceptible to opportunistic infections.  Lung transplantation is an option for 
patients with end-stage pulmonary vascular or parenchymal disease.  Among the potential post 
transplant complications, obliterative bronchiolitis (OB) is the most significant.  This disease 
affects 34% of lung transplant recipients and is accompanied by a high mortality rate resulting in 
1/3 of all deaths one-year post transplant.  OB is characterized by partial or complete luminal 
obliteration of the bronchioles causing obstruction of airflow though the exact pathogenesis is 
not well understood (37-39).  Respiratory viral infections have been postulated to be associated 
with the development of OB since immunosuppression leaves lung transplant recipients more 
susceptible to community-acquired infections (40-44).  RSV, a paramyxovirus, has been shown 
to cause the majority of viral infections in lung transplant recipients, however, there is evidence 
that other paramyxoviruses such as PIV and hMPV are likely to initiate both chronic and acute 
rejection (41).  The prevalence of OB increases from 34% to 47% in lung transplant recipients 
during respiratory virus season indicating that a respiratory virus could be involved in disease 
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pathogenesis (42,45).  Lung transplant recipients have therefore been examined in this study to 
determine the prevalence of hMPV infection in this patient population and to determine if hMPV 
infection is correlated with OB status. 
    hMPV is a negative  sense single stranded RNA virus  (13.3kb) that  has been added to the 
pneumovirus subfamily and metapneumovirus genus due to its genetic relatedness to the avian 
pneumovirus (APV).  hMPV is most similar to subtype APV-C, sharing an identical order of 
genes with 56%-88% homology at the nucleic acid level.  This illustrates a closer linkage 
between APV-C and hMPV than APV-C and APV subtypes A, B, and D (19).  Of all human 
viruses, hMPV is most similar to RSV differing only in the order of genes and the absence of 
two non-structural genes, NS1 and NS2, however, they are only 30% genetically homologous at 
the nucleic acid level (20) (Figure 1).  hMPV has two main genetic lineages, A and B, with two 
subtypes for each lineage (A1, A2, B1, B2) (21-23).  The genetic homology, at the sequence 
level, within each lineage is 77%-95% and between each lineage is 59%-87% with the N, F, L, 
and M genes being the most conserved and the G and SH genes being the least conserved (24).  
Both lineages circulate at the same time with no evidence of geographic clustering or antigenic 
drift (21), however different subgroups may circulate at various rates during different seasons 
(23).  There are reports of a patient being infected with both lineages in less than one month (25).  
Infection of hamsters with Can97-83 (strain A2) yields sera that neutralize infection with Can98-
75 (lineage B2) and vice versa.  This proves that the two separate lineages are highly related 
antigenically (48%) and are not distinguished serologically. (26)  
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Genetic similarity of hMPV and RSV 
 
Figure 1:  Genomic arrangement of RSV (top) and hMPV (bottom).  RSV is the most analogous human virus to 
hMPV as evidenced by their genetic similarity.  The only differences are the arrangement of genes and the presence 
of two nonstructural genes (NS1 and NS2) in RSV. 
 
    Viral infections can be detected in patient specimens by cell culture using a variety of 
continuous cell lines; respiratory viruses are usually detected from human and non human 
epithelial and kidney cell lines.  These tests often require long incubation times, as virus-induced 
cytopathic effect (CPE) only becomes evident after many rounds of viral replication and spread 
of virus to nearby cells.  The time needed to establish CPE depends on the virus and cell types, 
so results are often not available for 7-28 days after inoculation of the cell culture making it 
difficult to treat infected patients in a timely manner.  Thus, the amount of time needed to detect 
virus in a sample can vary greatly. Although culturing virus does take a long time to yield 
results, it is considered the gold standard for viral detection.   
    A more rapid, commercially available, culture system using R-Mix shell vials detects 
respiratory viruses in less than 24 hours.  This system contains a mixed monolayer of two cell 
lines, mink lung cells (Mv1Lu) and human adenocarcinoma cells (A549), that in combination 
support the detection of many viruses including influenza A and B, RSV, adenovirus, and PIV 1-
3, however, hMPV is not detected by this method.  An R mix vial is inoculated, cultured then 
stained with a pool of respiratory virus fluorescent antibodies.  Positive screens are further 
identified with the second R-Mix shell vial that is stained with virus specific monoclonal 
antibodies for diagnosis.  This type of testing will detect viral antigen prior to the production of 
CPE in an infected cell culture so is more rapid and very cost effective. 
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    hMPV has gone unrecognized for many years because it displays very slow replication 
kinetics in vitro, does not replicate efficiently in continuous cell lines, and requires trypsin for 
growth (1).  The virus can be cultured best in a rhesus monkey kidney cell line (LLC-MK2) 
(1,11,26,27) and studies have reported replication in HEp-2 and Vero cells (27-29), however it 
does not propagate in A-549, RD, 293, HT-29, and MDCK cells (11).  Although hMPV can 
infect LLC-MK2 cells, CPE is not seen until an average of 17.3 days post infection (d.p.i) (11).  
This makes it very difficult to detect hMPV in a timely manner and optimize patient treatment.   
    Recent advancements in molecular technology have vastly improved diagnostic tests for 
infectious diseases.  Nucleic acid amplification testing (NAAT) uses modern techniques such as 
polymerase chain reaction (PCR) and transcription assays to detect DNA or RNA from viral and 
bacterial pathogens.  These assays are more sensitive than culture techniques and take only a few 
hours to detect the presence of the pathogen.  Total nucleic acid can be extracted from patient 
specimens, which includes host DNA along with the presence of viral or bacterial nucleic acid in 
the case of infection.   
    PCR uses sequence specific primers and Taq polymerase to amplify target DNA by 
denaturing, annealing, and extending DNA sequences in a cyclic fashion.  Reverse transcriptase-
PCR (RT-PCR) has an initial RT step producing cDNA from RNA prior to amplification of the 
template.  Both of these techniques amplify DNA (or cDNA) every cycle in a binary fashion, 
resulting in large quantities of amplicon which can then be detected by gel electrophoresis.  In 
the case of real time PCR and real time RT-PCR, simultaneous amplification and detection 
occurs using molecular probes labeled with a fluorophore.  New minor groove binding (MGB) 
molecular probes are smaller and claim to be more specific than original probes.  Real time 
amplification has further improved clinical diagnostics by decreasing turn around time omitting 
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post amplification processing.  In addition, real time amplification is a closed system greatly 
reducing the risk of contaminating other specimens or reagents.  The real time PCR and RT-PCR 
systems are also quantitative, benefiting patient care in situations where the viral load is 
indicative of treatment.    
    Transcription assays, such as nucleic acid sequence based amplification (NASBA) and 
transcription mediated amplification (TMA), are alternative amplification systems to RT-PCR 
for RNA targets, however similar in theory.  These assays are isothermal in comparison to the 
cyclic variation in temperature during PCR.  NASBA uses three enzymes: AMV-RT, RNase H, 
and T7 RNA polymerase (Figure 2), while TMA uses only two, RT and T7 polymerase during 
amplification, though both produce RNA transcripts in a logarithmic fashion compared to the 
binary fashion of PCR.  NASBA has been shown to be more sensitive than RT-PCR for 
detection of some RNA viruses such as Dengue and West Nile virus (32, 33). 
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Real Time NASBA 
 
 
Figure 2:  Nucleic acid sequence based amplification (NASBA).  Isothermal amplification of RNA using three 
enzymes; AMV-RT, RNase H, and T7 RNA Polymerase.  The RNA  is reverse transcribed into cDNA      
which is then continuously transcribed back into RNA in a logarithmic fashion.   RNase H degrades RNA from the 
RNA/DNA duplex following the first strand of cDNA synthesis.  As the target is amplified, the molecular beacon 
emits fluorescence which is then detected by the EasyQ Analyzer.  
 
    Molecular tests in the clinical setting need appropriate positive, negative, and internal controls 
to assure that the tests are functioning correctly.  When amplifying nucleic acid using platforms 
such as PCR or NASBA, extraction and amplification controls are both needed.  This is to ensure 
that the entire process from beginning to end is working properly.  Positive and negative controls 
measure the ability of the assay to detect positive material as positive and fail to detect negative 
material as positive to determine if the entire test is working as it should.  Positive controls for 
viral testing are usually virus or viral nucleic acid containing the target sequences spiked into a 
same matrix to which the specimens are added.  Negative controls would be extracted in matrix 
alone.  Internal controls account for the integrity of each individual specimen indicating that 
NASBA Primers 
and Beacons 
anti-
sense 
 1. Reverse   
Transcriptase 
3. T7 RNA 
Polymersase
2. RNase H 
P1 
P2
Molecular Beacon
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RNA from virus was extracted and amplified as it should have.  This can be done by amplifying 
the RNA of “housekeeping” genes, such as ß-actin, which should be consistently present in 
certain specimens.  An alternative is to spike a non-human DNA or RNA virus control into each 
specimen prior to extraction.  This yields a consistent quantity of amplified internal control 
compared to a housekeeping gene that will vary between specimens.  With a quantitative real 
time amplification system, this will show if there is any form of inhibition.      
    RT-PCR has become the preferred method for diagnosing hMPV infections due to a decrease 
in throughput time and better sensitivity to other diagnostic assays.  The nucleoprotein (N) and 
polymerase (L) genes have been the most frequently utilized  targets due to their conserved 
nature across hMPV strains (7,30,31).  One of these assays has reported to detecting as low as 5-
10 copies of hMPV viral RNA (31).  There is, however, a lack of published real-time RT-PCR 
assays designed to specifically detect all four lineages of hMPV.  Though bioMérieux has been 
developing a real time NASBA assay for hMPV, nothing has been published.  The need to 
develop a real time RT-PCR that will detect all four sublineages of the virus is imperative 
because most of the published assays are designed to target the prototype A1 strain.       
    To design an optimal molecular assay for any infectious disease, a thorough genetic analysis 
of all strains of the pathogen must be considered prior to designing primers and probes for 
detection.  The sequences of all lineages and sub-lineages must be aligned to find conserved 
regions among all strains.  In addition, known single nucleotide polymorphisms (SNPs) should 
be noted such that primers are designed not to anneal where these mismatches frequently occur.  
The objective is to have an assay that will detect all positive samples from all genetic lineages of 
the virus or bacteria.   
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    There is no specific treatment available for hMPV.  Ribavirin and immune globulin designed 
for intravenous administration (IVIG) have broad antiviral activity and have inhibited this virus 
in vitro.  However, both treatments are extremely expensive, Ribavirin is a teratogenic agent and 
IVIG can interfere with live virus vaccines (e.g. MMR and varicella) (32).  A new sulfated sialyl 
lipid molecule, NMSO3, is known to have antiviral activity against RSV.  NMSO3 also shows 
inhibition of hMPV infection in vitro but not against other paramyxoviruses such as PIV and 
measles.  This agent diminishes syncytia formation and the secondary spread of infection. (33)  
Vaccines are not commercially available, though a recently described reverse genetic system 
(34) has been used to develop a recombinant hMPV virus lacking the attachment gene (G) (35).  
Hamsters inoculated with this rhMPV∆G virus experience a 40 fold decrease in viral replication 
compared to wt virus.  In addition, high titers of hMPV neutralizing serum antibodies are 
produced resulting in complete protection against wt virus challenge. (35)  This system 
represents a vaccine candidate with effective protection against hMPV to be studied further in 
primate models.   
    Human metapneumovirus is of great public health significance because it is an established 
community acquired respiratory virus that infects young children, elderly adults, and 
immunocompromised individuals causing bronchiolitis in the majority of cases.  In the United 
States alone, bronchiolitis is responsible for over 150,000 hospitalizations annually (5). Fatal 
cases have been reported in which hMPV is the sole pathogen isolated from lung tissue post 
mortem (11,36).  Due to its recent description, little is known about the severity of disease in 
specific patient populations.  Development of a sensitive diagnostic test and analysis of patient 
specimens in various cohorts will be beneficial for further understanding of hMPV.  In this 
study, an in-house real time RT-PCR assay specific for hMPV detection has been developed and 
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it is directly compared to a real time NASBA assay developed by bioMérieux.  Bronchoalveolar 
lavage (BAL) specimens from lung transplant recipients and nasal swabs from symptomatic 
children were examined for hMPV infection by both systems.  I hypothesize that detection of 
hMPV will occur in the lung transplant patient population resulting in severe infection causing a 
predisposition to the development of OB.  In addition, hMPV will be detected in the pediatric 
population at rates lower than RSV but higher than PIV.   
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2. Specific Aims  
I. Develop a specific and sensitive real time RT-PCR diagnostic assay for the detection of 
all four hMPV genetic lineages from respiratory specimens.  
II. Produce hMPV RNA transcripts of the gene targeted in the diagnostic assay for positive 
material to be used for standard curves and positive controls during specimen testing. 
III. Using the recently developed real time RT-PCR and previously developed real time 
Nucleic Acid Sequence Based Amplification (NASBA) diagnostic assays, test patient 
respiratory specimens for the presence of hMPV viral RNA in two separate cohorts: 
a. Bronchoalveolar lavage (BAL) specimens from immunosuppressed lung 
transplant recipients of all ages at University of Pittsburgh Medical Center 
(UPMC). 
b. Nasopharyngeal (NP) swabs from symptomatic children tested for Bordetella 
pertussis at Children’s Hospital of Pittsburgh (CHP). 
IV. Test patient respiratory specimens from both cohorts for other respiratory viruses 
(Adenovirus, Influenza A and B virus, RSV, PIV1-3) by R mix at the Clinical Virology 
Laboratory (CVL) at UPMC. 
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3. Methods  
3.1.  Sample Collection: 
    BAL specimens were collected from adult lung transplant recipients.  Bronchoscopies with 
bronchoalveolar lavage were performed at regular intervals according to the transplant protocol 
(1, 3, 6, 9, 12 months post-transplant) and as indicated by symptomatic events such as fever, 
radiographic infiltrates, and decreased forced expiratory flow as determined by spirometry.  
100ul of BAL specimen was stored in lysis buffer (bioMérieux, Durham, NC) at -80ºC in a total 
volume of 1ml. 
    Nasopharyngeal (NP) swabs from children with respiratory symptoms suspected of Bordetella 
pertussis were collected using the Childrens Hospital of Pittsburgh (CHP) specimen collection 
kit and instructions.  These specimens were collected during the 2004-2005 respiratory season 
from September to February.  An NP swab composed of Dacron fiber tip was inserted past the 
posterior nasopharynx, held in place for 15-30 seconds or until the patient coughed.  The tube 
was then placed in a tube of saline and transported to the lab where the swab was vortexed and 
wrung out such that the suspension can then be aliquoted (100ul) and stored at -80ºC until 
testing.   
 
3.2.  Virus and Viral RNA:  
    Viral isolates of hMPV strains Can97-83 (strain A2) and Can98-75 (strain B2) were kindly 
donated by Dr. Dean Erdman at the CDC (Atlanta, GA) and stored in TRIzol at -80ºC.  Both 
strains were cultured in MK2 cells and virus was taken at the third passage in June of 2003.   
    Can97-83 viral RNA (761ng/ul) was kindly provided by Dr. Ursula Buchholz at the NIH 
(Bethesda, MD).  Total RNA (840ng/ul) from infected vero cells and total RNA from uninfected 
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vero cells were taken 72 hrs post infection from 25cm2 flasks.  Total RNA was extracted using 
the RNeasy kit (Qiagen, Alameda, CA) in June of 2004.  
    Equine arteritis virus (EAV) was purchased from ATCC® (ATCC® Number: VR-796™) to be 
used as an internal control for RT-PCR of all respiratory specimens.  The virus was inoculated 
into a 75cm2 flask of vero cells near confluency.  Infection resulted in detachment of the 
monolayer from the flask in less than 24 hours.  The virus was harvested from the supernatant 
following sonication and stored (500ul:500ul) in minimal essential medium with 10% fetal 
bovine serum at -80ºC.  A 1/50 dilution of the virus was spiked into each specimen prior to 
extraction.      
 
3.3.  Nucleic Acid Extraction:   
    Isolation of viral nucleic acid from control material and patient specimens were performed 
using a NucliSens® automated extractor (bioMérieux, Durham, NC) according to the 
manufacturer’s instructions.  Lysis of 100ul of sample in 900ul of lysis buffer (bioMérieux, 
Durham, NC) occurs for 30 minutes and is brought to a total volume of 1ml.  Following lysis of 
the specimen, the internal control virus and 1ml of silica (53ul:90ul of silica to lysis buffer) was 
added.  The solution was transferred into a closed system cartridge and placed onto the 
instrument for extraction. The procedure takes approximately 1 hour and yields 50ul of eluate 
which can then be stored directly at -80ºC in the same tube. 
 
3.4.  Primer Design:   
    hMPV specific primers and MGB probes were designed for optimal detection of all four 
hMPV genetic lineages by real time RT-PCR targeting the N, F, and L genes (Figure 3).  
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Genbank accession numbers for all four lineages are AY355324, AF371337, AY355335, and 
AY355328 for the N gene, AY304360, AF371337, AY304362, and AY304361 for the F gene, 
and AF371337, AY525843, AY297749 and AY297748 for the L gene.  The primers and MGB 
probes were designed using Primer Express® software and the recommended primer/probe target 
regions were analyzed for variability among the four strains using Vector NTI 9.0.  Primer/probe 
targets were selected based on the highly conserved regions using degenerate bases where 
necessary.  All designed probes are 6-carboxy-fluorescein (FAM) labeled with an MGB 
quencher.  The Maertzdorf primer/probe set, designated as N1, uses a TAMRA quencher and 
targets the 3` end of the N gene.  The sequences of each primer/probe target are listed in Table 1.  
Target sites on hMPV genome 
 
 
 
 
 
 
Figure 3:  hMPV genome with N, F and L genes highlighted indicating location of each primer/probe set.  N1 is the 
Maertzdorf et al (31) set and N2 is the designed MGB set. 
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Table 1:  Primers and Probes 
 
Target Primer Sequence 
   
Forward 5`-CATCAGGTAATATCCCACAAAATCAG-3` 
Reverse 5`-GTGAATATTAAGGCACCTACACATAATAARA-3` N 
Probe 5`-FAM-TCAGCACCAGACACAC-MGB-3` 
   
Forward 1 5`-ARATGGCCGTTAGCTTCAGTCA-3` 
Forward 2 5`-AATGGCCGTTAGCTTCAGTCA-3` 
Reverse 5`-GTCTGAAAAYTGCCGCACAA-3` F 
Probe 5`-FAM-TTCAACAGAAGGTTCCTAAAT-MGB-3` 
   
Forward 5`-GGAGGAGGAGATCCAGTAGTYTTYT-3` 
Reverse 1 5`-CCACATGACTGATTGCTTCAGTTAA-3` 
Reverse 2 5`-TCCACATGACTGATTGCTTCAGT-3` L 
Probe 5`-FAM-AGAAGGACCCCTGATTT-MGB-3` 
   
Forward 5'-CATATAAGCATGCTATATTAAAAGAGTCTC-3 
Reverse 5'-CCTATTTCTGCAGCATATTTGTAATCAG-3' Maertzdorf primers Probe 5'-FAM-TGYAATGATGAGGGTGTCACTGCGGTTG-TAMRA-3' 
   
Forward 5`-GAAAATGTCTCTTCAAGGGATTCAC-3 
Reverse 5`-GCCAATTTTGCCGCTTCAT-3` Cloning primers RT GSP 5`-GCCTTGCGAGACATTATGATTTG-3` 
   
Forward 5`-GGCGACAGCCTACAAGCTACA-3` 
Reverse 5`-CGGCATCTGCAGTGAGTGA-3` EAV 
Probe 5`-FAM-TTGCGGACCCGCATCTGACCAA-TAMRA-3` 
 
Table 1:  List of primers and probes for hMPV real time RT-PCR detection, production of an N gene amplicon by 
conventional PCR, and equine arteritis virus (EAV) internal control amplification by real time RT-PCR.  The Y 
represents a pyrimidine (C or T) and the R represents a purine (A or G). 
 
3.5.  Real Time RT-PCR:   
    Reverse transcription and amplification of hMPV RNA was performed in a single tube using 
the in house developed N gene primers and probe, designated as N2 above, and One step RT 
qPCR MasterMix (Eurogentec, San Diego, CA) according to the manufacturer’s instructions.  
This 25ul reaction consisted of 2x reaction buffer, 8mM MgCl2, 200x EuroScript RT 0.25U/µl & 
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RNase Inhibitor 0.1u/ul, 300nM forward primer, 900nM reverse primer, 100nM probe, template 
RNA, and sterile H2O.  The amplification was carried out using an ABI PRISM® 7000 (Applied 
Biosystems, Foster City, CA) with the following cycling conditions: [RT step 48º C, 30 min]; 
[Taq Activation step 95º C, 10 min] x 1 followed by [PCR step 95º C, 15 sec; 60º C, 1 min] x 45. 
    Optimization of other hMPV assays were carried out under the same conditions however, 
primer, probe, and MgCl2 concentrations varied (Table 2).  The F1 assay consisted of 300nM of 
primers, 200nM of probe, and 8mM of MgCl2.  The F2 assay used 300nM of forward primer, 
900nM of reverse primer, 250nM of probe, and 6mM of MgCl2.  The L1 assay consisted of 
100nM of forward primer and probe, 900nM of reverse primer, and 5mM of MgCl2.  The L2 
target used 900nM of primers, 100nM of probe, and 6mM of MgCl2.  A previously published 
hMPV primer/probe set (Maertzdorf et al) targeting the 5`end of the N gene was used as a 
reference assay (Table 1). The Maertzdorf set consisted of 900nM primers, 100nM of probe, and 
5mM of MgCl2.   
    Amplification of EAV served as an internal control in every patient specimen to determine the 
integrity of the sample controlling for both extraction and amplification procedures.  The assay 
conditions for EAV amplification are the same as they are for hMPV described above, however, 
800nM of primers and 320nM of the probe were used to detect EAV (Table 1).  
 
3.6.  Real Time NASBA:   
    Real time NASBA was performed using NucliSens Basic Kit reagents (bioMérieux) on an 
EasyQ Analyzer (bioMérieux, Durham, NC) for 120 minutes according to the manufacturer’s 
instructions.  Working in collaboration with bioMérieux, hMPV specific primer/beacon mix was 
provided for virus amplification and detection.  Each sample was run in a 20-µl NASBA reaction 
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mixture containing; 5ul of template, 5ul of enzyme (1 enzyme sphere diluted in 55ul of enzyme 
diluent), and 10ul of reagent mastermix (1 reagent sphere, 80ul of reagent diluent, 16ul of 80mM 
KCl, 10ul of primer/beacon mix, and 14ul of H2O).  Template was added to the reagent 
mastermix and incubated at 65°for 2 min and 41° for 2 min.  Following the incubation, enzyme 
was added and mixed by briefly spinning and flicking the tubes.  Once sufficient mixing had 
occurred the specimens were loaded onto the EasyQ analyzer for amplification. 
 
3.7.  Viral Culture and Immunofluorescent Staining: 
    Two R mix shell vials (35-37°C) were inoculated with 200ul of clinical specimen according to 
the manufacturer’s instructions.  Each vial was centrifuged at 700 x g for 60 min and incubated at 
35°C.  Screening of the R-Mix shell vial at 18 to 24 h postinoculation was accomplished with the 
first of the two vials.  Coverslips were fixed with acetone and stained with a pool of respiratory 
virus fluorescent antibodies (adenovirus, influenza A and B virus, RSV and PIV 1-3) (Bartels, 
Inc, Issaquah, WA) according to the manufacturer's instructions.  Positive specimens were 
further identified with the second R-Mix shell vial by scraping and spotting eight-well slides. 
These slides were fixed with acetone again and stained with virus-specific monoclonal antibodies 
(Bartels, Inc, Issaquah, WA).  If the initial R-Mix screen was negative, the second vial was 
discarded.  
      
3.8.  Construction of N Gene Plasmid: 
    The hMPV N gene, in its entirety, was amplified by conventional two step RT-PCR from the 
Can97-83 viral RNA.  Primers were designed using Primer Express® software 2.0 looking at the 
first 1350 bases of the Can97-83 genome.  A gene specific primer (GSP) downstream of the N 
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gene located in the F gene region was designed for reverse transcription 900nM (5`-
GCCTTGCGAGACATTATGATTTG-3`).  The forward primer is upstream of the N gene start 
site (5`-GAAAATGTCTCTTCAAGGGATTCAC-3`) and the reverse primer is downstream of 
the N gene stop codon (5`-GCCAATTTTGCCGCTTCAT-3`).  Both primers were used at 
300nM concentration.  First strand cDNA synthesis was generated using Superscript III RT 
(Invitrogen, Carlsbad, CA).  A 10ul reaction consisting of 10ug of RNA, 2uM of primer, 10mM 
dNTP mix, and H2O is incubated at 65°C for 5 minutes.  Following incubation, 10x RT buffer, 
25mM MgCl2, 0.1 M DTT, RNaseOUT (40U/ul), and Superscript III RT (200U/ul) was added 
sequentially in a 2:4:2:1:1 ratio, respectively.  Reaction was incubated at 50°C for 50 minutes.  
Amplification of the N gene cDNA was done using a FailSafe™ PCR system (EPICENTRE® 
Biotechnologies, Madison, WI).  The failsafe premix D, containing dNTPs, buffer, and various 
amounts of MgCl2 and FailSafe™ PCR Enhancer with Betaine, was used for optimal 
amplification.  Amplification parameters were [98º C, 2 min hold; followed by 35 cycle of 98º C, 
20 sec, 54º C, 30 sec, 68º C, 1 min].  Presence of the amplicon was analyzed on a 1% agarose gel 
in Tris-EDTA (TE) buffer. 
    The PCR product was gel purified using the Wizard® SV Gel and PCR Clean-Up System 
(Promega, Madison, WI) according to the manufacturer’s instructions and ligated into the 
pGEM®-T Easy Vector (Promega, Madison, WI) overnight at 4ºC according to the 
manufacturer’s instructions.  The construct was then transformed into competent JM109 E. coli 
cells by heat shocking them at 42ºC for 45-50 seconds.  Cells were plated on LB/Amp/IPTG/X-
gal plates and screened for effective transformation by blue/white selection.  White colonies 
were cultured overnight in 3ml of ampicillin LB medium.  Plasmid DNA was extracted using the 
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Wizard® Plus SV Miniprep DNA purification System according to the manufacturer’s 
instructions (Promega, Madison, WI).   
    Insertion of the correct sequences into the plasmid was confirmed by digesting the plasmid 
with Pst I (Promega, Madison, WI) at 37ºC for 3 hours.  Orientation of the insert was confirmed 
by a double digest with both Pst I and Hind III (Promega, Madison, WI) at 37ºC for 3 hours.  
Digests consisted of 2ul of a 10x reaction buffer, 0.2ul of BSA, 5ul of DNA, and H2O to a 
volume of 20ul and were analyzed on a 1% agarose gel in TE buffer.   
    Plasmid templates were digested with Nco I (New England Biolabs, Inc, Beverly, MA) at 
37ºC for 2 hours.  After complete digestion, the restriction enzymes were heat inactivated at 
65ºC for 20 minutes and the DNA from the digest was isolated using the Wizard® SV Gel and 
PCR Clean-Up System (Promega, Madison, WI) according to the manufacturer’s instructions.   
    Under control of the SP6 promoter, the plasmid produced RNA run off transcripts of the entire 
N gene using 7.625ug of RNA and the Ribomax™ Large Scale RNA Production System 
(Promega, Madison, WI) according to the manufacturer’s instructions.  Following the 
transcription assay, the sample was DNase treated and RNA purified by phenol chloroform 
extraction.  The hMPV N gene transcripts were quantified using a spectrophotometer to measure 
the A260 yielding 4.563x1012 copies/ul.  A 1/300 dilution of the transcripts gave an A260 of 
0.256.  40ug/ml x 0.256 x 300=3.072ug/ul.  330Daltons x 1271 RNA bases = 419,430 molecular 
weight.  .000003072g / 419430 = 7.324x1012.  6.23x1023 x7.324x10-12 = 4.563x1012.  
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4. Results 
4.1.  Primer Design:  
    Three conserved genes (N, F and L) were selected as potential target sites to detect every 
hMPV strain from all known genetic lineages by real time RT-PCR.  One primer/probe set was 
designed for the N gene; however, a published set for the same gene was also analyzed (31). 
Two primer/probe sets were designed for the F gene using the same molecular beacon and 
reverse primer but with a different forward primer. Two primer/probe sets were also designed for 
the L gene using the same molecular beacon and forward primer however a different reverse 
primer was used.  Each primer and probe was designed such that there were minimal mismatches 
among the four strains.  Degenerate nucleotides were used in positions where bases varied 
between strains in order to enhance binding and amplification when applicable.  Every position 
containing a mismatch could not use degenerate bases due to the addition of an alternate base 
shifting the Tm out of range for appropriate PCR conditions.  Table 3 shows the alignment of 
each primer and probe with the corresponding sequences from each of the four strains.  The 
hMPV prototype strain NL/01/00 was used to analyze the A1 sequences.  A2 sequences were 
extracted from the NL/17/00 strain for N and F gene analysis and Can97-83 for L gene analysis.  
The NL/99/01 strain was used as a reference for B1 sequence analysis for all three genes.  The 
B2 sequences for the N and L genes were extracted from the NL/94/01 strain however the 
Can98-75 strain was used for the L gene analysis.  Each primer and probe is specific to 
metapneumovirus as evidenced by performing a blast search against all other known genetic 
sequences (data not shown). 
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Table 2:  Primer and probe alignment with corresponding sequences from all four hMPV 
genetic lineages 
 
M a e r t z d o r f  e t  a l  Forward Reverse Probe 
Primer Sequence CATATAAGCATGCTATATTAAAAGAGTCTC CCTATTTCTGCAGCATATTTGTAATCAG TGYAATGATGAGGGTGTCACTGCGGTTG 
A1 CATACAAGCATGCTATATTAAAAGAGTCTC CCTATTTCTGCAGCATATTTGTAGTCAG TGYAATGATGAGGGTGTCACTGCGATTG 
A2 CATACAAGCATGCTATATTAAAAGAGTCTC CCTATTTCTGCAGCATATTTGTAATCAG TGYAATGATGAGGGTGTCACTGCGGTTG 
B1 CATATAAGAATGCTATATTAAAAGAGTCTC CCTATCTCAGCAGCATATTTGTAATCAG TGYAATGATGAAGGTGTCACTGCGATTG 
B2 CATATAAGAATGCTATATTAAAAGAGTCTC CCTATCTCTGCAGCATATTTGTAATCAG TGYAATGATGAAGGTGTCACTGCGATTG 
    
N gene Forward Reverse Probe 
Primer Sequence CATCAGGTAATATCCCACAAAATCAG GTGAATATTAAGGCACCTACACATAATAARA TCAGCACCAGACACAC 
A1 CATCAGGTAATATCCCACAAAATCAG GTGAATATTAAGGCACCTACACATAATAAGA TCAGCACCAGACACAC 
A2 CATCAGGCAATATTCCACAAAATCAG GTAAATATTAAGGCACCTACACATAATAAGA TCAGCACCAGACACAC 
B1 CATCAGGTAACATCCCACAAAACCAG GTGAATATTAGGGCACCTACACATAATAAAA TCAGCACCAGACACAC 
B2 CATCAGGCAACATCCCACAAAACCAG GTGAATATTAAAGCACCTACACACAATAAAA TCAGCACCAGACACAC 
     
F gene Forward 1 Forward 2 Reverse Probe 
Primer Sequence ARATGGCCGTTAGCTTCAGTCA AATGGCCGTTAGCTTCAGTCA GTCTGAAAAYTGCCGCACAA TTCAACAGAAGGTTCCTAAAT 
A1 AAATGGCCGTTAGCTTCAGTCA AATGGCCGTTAGCTTCAGTCA GTCTGAAAATTGCCGCACAA TTCAACAGAAGGTTCCTAAAT 
A2 AAATGGCTGTTAGCTTCAGTCA AATGGCTGTTAGCTTCAGTCA GTCTGAAAATTGCCGCACAA TTCAACAGAAGGTTTCTAAAT 
B1 AGATGGCTGTCAGCTTCAGTCA GATGGCTGTCAGCTTCAGTCA GTCTGAAAACTGCCGCACAA TTCAACAGAAGATTTCTAAAT 
B2 AGATGGCTGTCAGCTTCAGTCA GATGGCTGTCAGCTTCAGTCA GTCTGAAAACTGCCGCACAA TTCAACAGAAGATTCCTAAAT 
     
L gene Forward Reverse 1 Reverse 2 Probe 
Primer Sequence GGAGGAGGAGATCCAGTAGTYTTYT CCACATGACTGATTGCTTCAGTTAA TCCACATGACTGATTGCTTCAGT AGAAGGACCCCTGATTT 
A1 GGAGGAGGAGATCCAGTAGTCTTCT CCACATGACTGATTGCTTCAGTTAA TCCACATGACTGATTGCTTCAGT AGAAGGACCCCTGATTT 
A2 GGAGGAGGAGATCCAGTAGTCTTCT CTACATGGCTGATTGCCTCAGTTAA TCTACATGGCTGATTGCCTCAGT AGAAGGACCCCTGATTT 
B1 GGAGGGGGAGATCCAGTAGTTTTTT CCACATGGCTGAGGGCTTCAGTTAG TCCACATGGCTGATTGCTTCAGT AGAAGGACTCCCGATTT 
B2 GGAGGAGGAGACCCAGTAGTCTTCT CCACATGACTGATTGCTTCAGTTAA TCCACATGGCTGATTGCTTCAGT AGAAGGACTCCTGATTT 
 
Table 2:  Alignment of primer/probe sets with corresponding sequences from each of the four hMPV genetic 
lineages.  The red bases indicate a mismatch and the blue bases indicate the use of a degenerate nucleotide.  The Y 
represents a pyrimidine (C or T) and the R represents a purine (A or G).  The Maertzdorf et al primer/probe set in 
addition to the designed N, F, and L primer/probe sets are included in the table. 
 
 
4.2.  hMPV Real Time RT-PCR Optimization: 
    
    Each of the six real time RT-PCR assays were optimized using a high concentration (20ng) of 
Can97-83 (strain A2) hMPV viral RNA.  Cross titrations of primers ranging from 100-900nM 
final concentration and probes ranging from 100-250nM final concentration were performed in 
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addition to an MgCl2 titration ranging from 5-10mM.  The optimal concentrations for each assay 
and their respective Ct values are listed in Table 3.    
 
Table 3:  Optimal conditions for each hMPV real time RT-PCR assay 
 
Target Forward Primer (nM) 
Reverse 
Primer (nM) Probe (nM) 
MgCl2 
(mM) Ct Value 
Maertzdorf 900 900 100 5 17.58 
N gene  300 900 100 8 21.11 
F gene (1) 300 300 200 8 19.81 
F gene (2) 300 900 250 6 20.83 
L gene (1) 100 900 100 5 24.76 
L gene (2) 900 900 100 6 25.08 
 
  Table  3:  Optimal conditions of each target using 20ng of hMPV Can97-83 (Strain A2) RNA.  Mean Ct values are 
representative of duplicate samples 
 
    hMPV virus Can97-83 (strain A2) and Can98-75 (strain B2) were used to determine the 
capability of each assay to detect both main lineages of the virus (Table 4).  This is a lower 
dilution than the amount used during the original optimization.  This dilution was used in order 
to detect a concentration of virus that would more likely be seen in patient specimens.  Most of 
the assays detected hMPV with similar efficiency during the initial optimization using RNA 
from strain A2.  The F and L targets failed to detect RNA from strain B2 with comparable 
efficiency to strain A2.  The Maertzdorf set detects high quantities of strain A2 very well; 
however, when both strains of the virus are diluted the ability of the primer/probe set to amplify 
virus appears to be abolished.  This is due to amplifying hMPV under different conditions than 
used by the Maertzdorf lab.  We can not alter our conditions and parameters due to maintaining a 
consistent platform to amplify many targets at once.  The N gene target has the ability to detect 
both main lineages without a significant decrease in the limit of detection.  
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Table 4:  Detection of hMPV strain A and B by real time RT-PCR 
 
Target Can97-83 (Ct) Can98-75 (Ct) 
Maertzdorf Undet Undet 
N 29.77±0.36 31.16±1.31 
F1 29.97±1.09 35.97±0.42 
F2 29.52±0.87 35.73±0.42 
L1 33.57±0.93 37.80±1.17 
L2 34.33±1.15 33.09±1.81 
 
Table 4:  Sensitivity of each target amplifying a 1/1000 dilution of CDC hMPV RNA extracted in lysis buffer from 
strains Can97-83 (A2) and Can98-75 (B2).  Mean Threshold cycle (Ct) values are representative of duplicate 
samples from two separate experiments.   
 
    Both strains of hMPV were quantitated by real time RT-PCR using RNA transcripts and the N 
gene primers.  The superior of the two primer/probe sets for each gene was used to determine the 
lower limits of detection.  The limit of detection for each gene was determined by amplifying a 
serial dilution of hMPV strains A and B ranging from 100,000-10 copies.  The lower Ct values 
using the N target for detection indicate an impressive limit of detection for both main lineages 
of the virus as shown in figure 4A-B.  The limit of detection for each target is shown in figure 
4C.  The N target detected 100 copies of both strains A and B, the F target only detected 1,000 
copies of strain A and failed to detect 100,000 copies of strain B, and the L target detected 100 
and 10,000 copies of strain A and B respectively.  
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Limits of Detection for hMPV strains A and B using real time RT-PCR 
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Target 
Strain 100,000 copies 
10,000 
copies 
1,000 
copies 
100 
copies 
10    
copies 
Can97-83 (A2) + + + + - N gene Can98-75 (B2) + + + + - 
Can97-83 (A2) + + + - - F gene Can98-75 (B2) - - - - - 
Can97-83 (A2) + + + + - L gene Can98-75 (B2) + + - - - 
 
Figure 4:  Detection of serially diluted hMPV RNA from strains A(top left panel) and B (top right panel) by N 
(blue), F (red), and L (green) targets by real time RT-PCR.  Limit of detection for each target.  
 
    Detection of hMPV in nucleic acid from clinical specimens by real time RT-PCR utilizing the 
N target was validated with hMPV negative BAL fluid from lung transplant recipients.  Serial 
dilutions of hMPV RNA were spiked into 100ul of clinical specimens prior to extraction.  As a 
control, the same dilutions of viral RNA were spiked into lysis buffer without specimen and 
extracted alone.  Figure 5 shows the detection of hMPV under both of these conditions in 
addition to amplified RNA from the same dilutions without an extraction procedure.  Various 
quantities BAL fluid ranging from 10ul to 100ul were extracted and amplified to see if any 
inhibitory effect occurred.  There was no inhibition noted up to 100ul of specimen tested (data 
not shown).  Proteinase K treatment of BAL specimens prior to addition of the lysis buffer did 
A B 
C 
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not show any advantage for viral detection (data not shown).  These data confirm that hMPV 
RNA can be detected in clinical patient specimens.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Detection of Can97-83 hMPV RNA by real-time RT-PCR.  10, 1.0, 0.1, and 0.01ng of hMPV RNA was 
spiked into either hMPV negative BAL specimens (-----) or Lysis Buffer alone (- - -) followed by extraction of total 
nucleic acid.  Amplification of extracted RNA was performed in duplicate using the Nucleoprotein (N) target.  
Equivalent amounts of amplified (non-extracted) viral RNA are shown by (-) to compare with extracted RNA. 
 
    Equine arteritis virus (EAV), an RNA virus, was used as an internal control to monitor 
extraction and amplification of all patient specimens.  A 1:50 dilution of cultured virus was 
spiked into each specimen prior to extraction.  Specimens are considered inhibited and must be 
repeated if the EAV Ct value is >30.77.  This was determined by taking the average Ct 
value+2SD of 80 BAL specimens. Detection of the internal control by real time RT-PCR using 
published target sequences was optimized for the ABI PRISM® 7000 on our platform.  The EAV 
caused no inhibition of hMPV amplification even at low levels of spiked hMPV (Table 5) 
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Table 5:  EAV optimization as an internal extraction and amplification control 
 
 
 
 
Table 5:  Equine Arteritis Virus (EAV) is used as an internal extraction and amplification control.  A 1:50 dilution 
of EAV was spiked into the BAL samples along with 0.1pg, 1pg, 10pg, 100pg, 1ng, and 10ng of hMPV RNA.  hMPV 
was also extracted and amplified without EAV.  Numbers represent the Ct value +/- SD of 2 experiments.  UNDET 
is undetermined and ND is not done. 
 
 
4.3.  hMPV Real Time NASBA Optimization: 
     
    bioMérieux has developed a real time NASBA assay for hMPV detection, and our lab has had 
the opportunity to evaluate this test on lung transplant recipients.  Optimization of the assay was 
performed by bioMérieux and all information regarding the assay was proprietary, so the target 
was unknown.  The primers, beacon, and KCl concentrations were defined with no room for 
adjustment, so the assay was performed according to bioMerieux’s instructions.  The negative 
cut-off value was defined in our laboratory by testing 140 negative patient specimens, per PCR.  
The mean ∆value from each reaction was multiplied by the ratio of max/min [Mean ∆value x 
(max∆value / min∆value)] to get a cut off ∆value of 0.041. 
 
 
4.4.  Construction of N Gene Plasmid: 
     
    A plasmid containing the entire hMPV N gene was constructed and used to produce RNA run-
off transcripts.  This RNA was then used as a positive control for the quantitation of hMPV by 
ND 25.4±0.29 26.3±0.41 26.3±0.41 25.9±0.49 24.8±0.02 EAV 
Detection 
UNDET 37.6±0.33 35.8±1.02 30.0±0.49 27.7±0.19 21.5±0.04 
HMPV with 
EAV 
40.2±0.18 40.8±2.19 33.1±0.13 30.6±0.21 26.9±0.49 22.3±0.34 HMPV alone  
0.1pg 1pg 10pg 100pg 1ng 10ng hMPV load 
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real time RT-PCR.  Known copy number of hMPV RNA is amplified as a standard curve during 
every experiment in order to quantitate positive specimens.  This plasmid was constructed by 
ligating a 1250 bp PCR fragment containing the Can97-83 N gene into a pGEM®-T Easy Vector 
(Figure 6).  The N gene was amplified by conventional two step RT-PCR using primers upstream 
and downstream of the gene (Figure 6B).   
 
Construction of an hMPV N gene plasmid  
 
 
    
Figure 6:  Schematic of construction of an hMPV N gene plasmid under the control of either SP6 or T7 depending 
on the orientation, A.  The cloned N gene amplicon is 1250bp shown on a 1% agarose gel in duplicate, B.  Note the 
Pst I sites within the insert and the NcoI site on the vector adjacent to the insert. 
 
    The PCR fragment was gel purified and ligated into a pGEM®-T Easy Vector overnight which 
was then transformed into JM109 cells.  Plasmid DNA was extracted from twelve selected 
colonies thought to be expressing the plasmid.  Of the twelve colonies picked, three of them 
actually contained the insert as evidenced by the presence of a 950bp fragment following a Pst I 
hMPV N gene
1185 
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Designed N gene 
hMPV genome  M
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A 
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digest (Figure 7A). The insert contains two Pst I restriction sites 950bp from each other (Figure 
6A).  The orientation of the insert is important because it will determine which RNA polymerase 
will be used for the transcription reaction.  To determine the orientation of the insert, a double 
digest with Sac I and Hind III will yield either an 850bp fragment or a 620bp fragment (Figure 
7C).  Two of the three colonies (colonies 9 and 10) had the insert in the 3`-> 5 directions under 
control of the SP6 promoter.  Colony 12 had the insert in the 5`->3` direction under control of 
the T7 promoter. (Figure 7B)   
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N gene Plasmid Restriction Digests 
                                     
 
                                                                    
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: N gene plasmid DNA. The presence of a 950bp fragment indicates efficient ligation and transformation of 
the insert, three of the twelve picked colonies had the insert present (circled in red).  The plasmid DNA was ran on a 
1% agarose gel in TE buffer in the cut and uncut conformation respectively, A.  Orientation of the inserts were 
determined by performing a double digest with Hind III and Sac I, two of the three were in 3`->5` direction under 
the control of the SP6 promoter and the 12th colony is in the 5`->3` orientation under control of the T7 promoter, 
B,C. 
 
    The original 9th colony in the 3`->5` orientation (Figure 8A) and the original 12th colony in the 
5`->3` orientation (Figure 8B) were transformed and cloned again in order to make a stock of 
each plasmid for each orientation. 
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N gene plasmid under control of two different promoters 
 
 
Figure 8:  Plasmid DNA from colonies, A-E2, are from the 9th (A) and 12th (B) original colonies producing an 850bp 
band and a 620bp band respectively when double digested with SacI and Hind3. The bands on the left are uncut 
plasmid DNA and the  bands on the right have been double digested.  12th colony: all 5 colonies have 620bp band. 
Left bands are uncut, Right bands are cut 
 
    In vitro transcription of the N gene was accomplished using the Ribomax™ Large Scale RNA 
Production System.  The plasmid was linearized cutting the vector portion of the plasmid just 3` 
of the N gene insert using an Nco I site.  Under control of the SP6 promoter RNA transcripts 
were made solely of the hMPV N gene (Figure 6A).  The run-off transcripts were quantified by 
measuring the A260 using a spectrophotometer yielding a final concentration of 4.563 x 1012 
copies/ul.    
  
   
4.5.  Limit of Detection for N Gene Real Time RT-PCR: 
     
    The hMPV real time RT-PCR targeting the N gene was developed to detect all four genetic 
lineages of the virus.  To determine the capability of the test to detect various strains of the virus, 
a limit of detection assay was performed using the two main lineages, Can97-83 and Can98-75, 
for strains A2 and B2 respectively (Figure 9).   Half log intervals were amplified from 100,000-
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10 copies for both viruses and showed comparable limits of detection for the two strains 
detecting 50 and 100 copies respectively (Table 6).    
 
N gene hMPV Real time RT-PCR Limits of Detection 
 
             hMPV Can97-83 (Strain A)                             hMPV Can98-75 (strain B) 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 9:  Amplification plots of serially diluted hMPV strains A (left panel) and B (right panel) detected by real 
time RT-PCR using the N target.  100,000 copies (red left), 10,000 copies (green), 1,000 copies (blue), 100 copies 
(purple), and 10 copies (red right).   
 
 
4.6. Limit of Detection for Real Time NASBA: 
 
        hMPV strains A and B were amplified using real time NASBA with discordant limits of 
detection between the two main lineages.  The NASBA assay could detect as low as 50 copies of 
strain A2 yet only 1000 copies of strain B2 (Table 6).  Figures 10 and 11 show the actual 
amplification plots for serial dilutions of hMPV strains A and B.  The fluorescence of each 
amplification from the serial dilutions was plotted against time in figure 12.   
 
 
 
 
 
 
 
 
hMPV Strain A (Can97-83) hMPV strain B (Can98-75)
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NASBA detection of hMPV strain A 
 
           
            100,000 copies                                50,000 copies                                   10,000 copies 
                       
             5,000 copies                                  1,000 copies                                         500 copies 
           
              100 copies                                           50 copies                                         10 copies 
 
Figure 10:   Real time NASBA limit of detection assay for hMPV strain A.  This is not a quantitative test however the 
negative cut-off is ∆value 0.041. 
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NASBA detection of hMPV strain B 
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Figure 11:  Real time NASBA limit of detection assay for hMPV strain B.  This is not a quantitative test however the 
negative cut-off is ∆value 0.041. 
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Fluorescence emission by hMPV real time NASBA detection 
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Figure 12:  Fluorescence plot of samples from a serial dilution of hMPV detected by real time NASBA.  Strain A 
(top panel) is more sensitive than strain B (bottom panel). 
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Table 6:  Limits of Detrection for real time RT-PCR and real time NASBA 
 
Table 6:  Comparison of the real time RT-PCR and real time NASBA limits of detection for the amplification and 
detection of hMPV. 
 
 
4.7.  Specificity of the hMPV N Gene Real Time RT-PCR Assay: 
      
    The hMPV N gene real time RT-PCR assay was developed to detect all four genetic lineages 
of the virus.  To ensure that false positives do not occur, a panel of respiratory virus RNA was 
assayed for amplification.  Using the N target, RNA from influenza A and B virus, respiratory 
syncytial virus, parainfluenza virus 1-3, adenovirus, and SARS-CoV failed to amplify, indicating 
that this assay is specific to hMPV alone.  
 
4.8.  Detection of hMPV in Adult Lung Transplant Recipients: 
 
    A total of 234 BAL specimens from 114 lung transplant recipients were tested for hMPV 
infection by both real time RT-PCR and real time NASBA.  Samples were collected from 5-13-
04 to 4-11-05 spanning an 11 month period.  The patient’s ages ranged from 22-75 years old 
with an average age of 51.7.  The cohort was comprised of 41.2% males and 58.8% females.  3 
specimens were positive for hMPV by RT-PCR (1.28%) including one specimen that was not 
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detected by NASBA; however, NASBA detected 4 (1.71%) hMPV positive specimens, including 
2 that were not detected by RT-PCR.  There was a total of 5 samples (2.14%) from different 
patients positive for hMPV all occurring during the late winter season between 2-17-05 and 4-1-
05 (Table 7).  All samples included in the study extracted and amplified without inhibition as 
evidenced by positive EAV Ct values (data not shown).   
    An immunofluorescence assay was used to determine the prevalence of other respiratory 
viruses in the lung transplant recipients; flu A (0%), flu B (0%), RSV (0%), PIV1-3 (0%), and 
Adenovirus (0.0043%).  In this patient population, hMPV was the most prevalent respiratory 
viral infection (2.14%).  Two patients, 1124 and 1119, were positive for CMV antigenemia from 
the BAL specimens, which were also positive for hMPV.  Patient 1130 was the only positive 
patient during a routine follow-up, the rest of the positive patients underwent bronchoscopies due 
to respiratory symptoms.  Patient 1119 was rejecting the graft at the time of hMPV infection.  
Patient 1396 was positive for hMPV in addition to Candida albicans, Streptococcus viridans, 
Neisseria, and Propionibacterium Diphtheroids infections.  Patient 1130 was positive for hMPV 
on 2/17/05 and then negative on 4/4/05 indicating that the infection cleared and is not persistent.  
During this time, the patient was positive for hMPV in addition to Candida albicans and 
Streptococcus viridans.   
    This study was on specimens taken throughout the entire year.  hMPV infection is known to 
be most prevalent during the late winter months (February-April).  In this cohort, the prevalence 
of hMPV infection is 9.6% during this time period establishing it as a prevalent pathogen in this 
patient population during the late winter months.   
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Table 7:  hMPV positive lung transplant recipients 
 
Pt ID Date PCR Copies/ml NASBA IC 
1119 4/1/2005 Pos 11,865 Neg Pos 
1124 3/15/2005 Pos 18,895 Pos Pos 
1130 2/17/2005 Pos 12,100 Pos Pos 
1396 2/22/2005 Neg - Pos Pos 
1422 3/23/2005 Neg - Pos Pos 
 
Table 7:  List of hMPV positive patients from the lung transplant cohort.  Quantitation of specimens were only done 
on PCR positive.  Internal Control (IC) were all positive.   
 
4.9.  Detection of hMPV in Symptomatic Children: 
 
     328 nasopharyngeal (NP) swabs taken from children during the 2004-2005 winter season were 
tested for Bordetella pertussis at Childrens Hospital of Pittsburgh (CHP).  Using these 
specimens, a retrospective study was designed to look for hMPV infection by real time RT-PCR.  
The specimens were collected by doctors, nurses, and other health care providers at CHP in the 
emergency department, nursing units, and fast track unit as well as from other institutions such 
as Latrobe Hospital, West Penn, Mercy Hospital, and Molecular Diagnostics (UPMC).  Samples 
were collected from 09-09-2004 until 02-01-2005 during the early and middle winter season.  
Samples for late winter months could not be obtained due to requirements of CHP not releasing 
samples until 3 months after the collection date.  The patients ranged in age from 14 days to 59 
years old averaging 6.65 years.  The study included 53.5% male and 46.5% female patients. 
    There were only 6 (1.83%) reproducible positives by real time RT-PCR and 2 of these were 
also positive for Bordetella pertussis indicating a coinfection (Table 8).  7 other patients tested 
positive for hMPV, however, showed very low levels of RNA near the limit of sensitivity and 
were not reproducible.  Due to the lack of hMPV NASBA reagents provided by bioMérieux, we 
were unable to assay all of the patient specimens by this detection method.  However, the 6 
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reproducibly positive RT-PCR samples were tested for hMPV by NASBA and only 2 of these 
patients were positive (Table 8).   
  45 (13.7%) of the specimens were positive for Bordetella pertussis making it the most prevalent 
pathogen present in this cohort.  30 specimens from this study were tested for other respiratory 
viruses indicating the following prevalence’s; Flu A (3.3%), Flu B (0%), RSV (3.3%), PIV1-3 
(0%), Rhinovirus (3.3%) and Adenovirus (3.3%).  These other respiratory specimens were 
detected by culture methods so the detection may not be as sensitive as the hMPV PCR.  Real 
time RT-PCR detected hMPV in 6.67% of these same 30 specimens.  
 
 
Table 8:  hMPV positive patients suspected of Bordetella pertussis 
 
Pt ID Date Age B. pertussis
hMPV 
PCR Copies/ml 
hMPV 
NASBA IC 
78 10/18/2004 40Y Neg Pos 112,351 Neg Pos 
179 11/28/2004 21M Neg Pos 43,148,150 Neg Pos 
217 N/A 7Y Pos Pos 1,948,864 Neg Pos 
299 1/12/2005 10M Pos Pos 3,819,584 Pos Pos 
309 1/16/2005 26M Neg Pos 8,227,103 Neg Pos 
311 1/18/2005 7M Neg Pos 149,000,000 Pos Pos 
 
Table 8:  List of hMPV positive patients from CHP study.  Coinfection occurred in 2 of these patients.  Internal 
Control (IC) were all positive. 
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5. Discussion 
    This newly described paramyxovirus has been detected throughout the world and has come to 
be known as a major cause of community acquired respiratory infections.  Since its discovery in 
2001, hMPV has been found primarily in children, though elderly and immunosuppressed 
individuals have shown to be susceptible to infection.  Recently, it has been established that there 
are four different genetic lineages of hMPV and all four circulate at the same time with no 
evidence geographic clustering or antigenic drift.  Because of this, a diagnostic test capable of 
detecting all lineages and strains of the virus is essential for proper diagnosis such that infections 
are not missed due to assay bias.  In this study, a real time RT-PCR assay was designed and 
developed to detect all lineages of the virus and it was compared to an hMPV real time NASBA 
assay designed by bioMérieux which is currently in developmental stages of production.  Our 
laboratory has been working in collaboration with them to evaluate their assay and test patient 
specimens since they do not have easy access to patient samples.   They provided us with 
amplification kits and hMPV sequence specific primers and a molecular beacon but have just 
optimized the internal control (IC) for this assay, so it was not included in the study. This IC 
needs to be used prior to extraction and amplification and then validated for real time NASBA.  
Both tests were used to detect hMPV infection in lung transplant recipients as well as 
symptomatic children suspected of Bordetella pertussis.   
    The RT-PCR was designed to target conserved sequences among all four strains of the virus.  
Degenerate bases were used when able to account for variability between the strains in order to 
detect as many infections as possible.  The degenerate bases noted by an R indicate either an A 
or G in the position such that 50% of the synthesized primers will contain an A and the other 
50% will contain a G.  The degenerate bases noted by a Y indicate either a C or T in the position 
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such that 50% of the synthesized primers will contain a C and the other 50% will contain a T.  
Five real time RT-PCR assays were developed and in combination with a published set (31) were 
all compared for strain sensitivity and overall ability to detect virus.   
    The Maertzdorf primer/probe set (31) appeared to detect hMPV better than the designed MGB 
sets based on high quantity strain A2 RNA (Table 3).  When comparing sensitivities of the 
various strains, this published set failed to amplify lower levels of hMPV RNA, though they 
claim to be able to detect as low as 10 copies of RNA (Table 4).  Primers and probe were ordered 
a second time to make sure they were not poorly synthesized oligonucleotides and the same 
problems occurred.  This discrepant report is probably due to the use of different molecular 
platforms.  They used a universal mastermix from a different company than used in our lab and 
the PCR conditions varied as well as the primer/probe concentrations.  Our amplification 
parameters and one step mastermix must remain consistent such that we can amplify many 
targets at one time without having to change conditions.   
    The N gene target utilizing an MGB molecular probe has the best overall sensitivity compared 
to the other RT-PCR assays in addition to the NASBA assay developed by bioMérieux (Figure 4 
and Table 6).  The N gene RT-PCR as well as the NASBA assays can detect as low as 10 copies 
of strain A2 RNA however, this limit of detection is not always reached so it is reported that the 
assay can only detect 50 copies of hMPV RNA (Figure 9).  The ability of the RT-PCR assay to 
detect hMPV viral RNA in actual specimens was tested by spiking whole virus into BAL 
specimens prior to extraction.  The virus was detected more efficiently when extracted in actual 
BAL samples compared to lysis buffer (control matrix) (Figure 5).  Both of these sample types 
were compared to the sole amplification without extraction of hMPV RNA.  There is an expected 
loss of viral RNA during the extraction procedure as reflected by a slight increase in Ct value for 
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these samples.  This indicates that hMPV can be detected in patient specimens using the 
automated extraction method we are currently using in our laboratory. 
    The use of an adequate internal control is imperative for molecular based assays.  A non 
human virus can be used as a quantitative internal control because a known amount is spiked into 
each specimen prior to extraction.  In addition, using a virus mimics the extraction and 
amplification of the target virus (hMPV).  Equine arteritis virus (EAV) is used in this system to 
determine if there is any form of inhibition throughout the extraction and amplification process.  
The average Ct value+2SD of 100 EAV spiked samples set the cut-off value for inhibition at a Ct 
value of 30 or higher.  This internal control served as a means to determine when a negative 
sample should be repeated. 
    For a quantitative real time RT-PCR assay, every experiment contains a serial dilution of 
positive material in order to accurately quantitate positive specimens.  For this reason, sufficient 
amounts of control material will be needed for future testing since this assay was developed with 
the intention to go on-line at the University of Pittsburgh Medical Center (UPMC) as a 
diagnostic test in the clinical virology laboratory.  Construction of a plasmid containing the 
target sequence was completed which can be used for production of RNA runoff transcripts 
producing high copy number of the gene of interest.  A plasmid containing the entire N gene was 
constructed due to the difficulty of culturing hMPV and the lack of commercially available 
hMPV RNA.   
    Though hMPV has been detected in immunosuppressed individuals, there has yet to be a study 
determining the prevalence of hMPV in lung transplant recipients; this is the first report of such a 
study.  The University of Pittsburgh Medical Center is a global leader for solid organ transplants. 
This institution performs more than fifty lung transplants per year and follows over two hundred 
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fifty lung transplant recipients for routine post transplant examination.  BAL samples are 
collected from lung transplant recipients at 3, 6, 9, and 12 months post transplant, as well as 
every 6 months after that for a maximum of 3 years.  In addition to routine collection, specimens 
are also collected from symptomatic transplant recipients with possible respiratory infections.  
BAL specimens from lung transplant recipients were collected at routine visits in addition to 
visits due to symptomatic events.      
    In this one year study, 2.14% of all patients were positive for the virus.  Though this is a low 
percentage, these specimens were collected all year long, though hMPV is a late winter virus.  In 
addition, many of these patients have come to see the physician because of routine post 
transplant follow-up and have no signs or symptoms of respiratory viral infection.  When 
monitoring the late winter months, 9.6% of the patients were positive for hMPV establishing it as 
a prevalent pathogen in this patient population during the late winter months.  Every specimen 
was tested for other respiratory viruses by an immunofluorescense assay; however all were 
negative except one adenoviral infection.  
The lack of other respiratory viruses indicates that hMPV could be a major pathogen in this 
population.   
    Knowing that this virus primarily infects children, this assay was used to detect hMPV in NP 
swabs from children suspected of Bordetella pertussis.  Patients infected with pertussis present 
with a broad range of symptoms indicating there could be a secondary infection due to the 
pertussis infection.  It is possible that pertussis infection along with a respiratory viral infection 
may result in a series respiratory illness.  In this study only 1.83% of the specimens were positive 
for hMPV however 13.7% were positive for Bordetella pertussis (Table 8).  In addition 2 
(33.3%) of the 6 positive patients were co-infected with B. pertussis.  There were 7 patients that 
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were detected as positive for hMPV then when re-amplified, they failed to amplify.  This is due 
to the limit of detection not being able to amplify RNA of low levels on a consistent basis.  All 
of the positives that did not re-amplify had Ct values of 38-44.  bioMérieux did not provide new 
reagents for this study so all 328 were not tested for hMPV by real time NASBA.  However, 
there were enough reagents left over to test the RT-PCR positives by NASBA, and only 2 were 
positive (Table 8).  There is future work to do with this project starting with sequencing all 
patient positives to determine the strain prevalence in Pittsburgh.    
    This pediatric study was cut short by not being able to access the samples from February to 
April (the peak hMPV months).  I feel that if the study could have accessed these samples prior 
to three months after specimen collection, a higher incidence of hMPV infection would have 
been noted.  A majority of the patient positives were in January as were the non-reproducible 
positives.  Only 30 of these patient specimens were cultured for other respiratory viral infection.  
Of these, one specimen was positive for rhinovirus (3.3%), one was positive for adenovirus 
(3.3%), one was positive for influenza A (3.3%) virus, and one was positive for RSV (3.3%).  
Out of this group of patients, 2 were positive for hMPV PCR (6.6%).  Though a small number of 
patients were included, hMPV was the most prevalent respiratory virus in the group.  This study 
should proceed with testing the patient specimens for hMPV during the late winter months of 
February-April.       
    In conclusion a real time RT-PCR assay was developed to detect all four lineages of hMPV 
targeting a conserved region of the N gene.  This assay was compared to an hMPV real time 
NASBA in the developmental stages of production by bioMérieux.  The limits of detection for 
the RT-PCR for both of the main lineages are similar when comparing Can97-83 (Strain A2) and 
Can98-75 (Strain B2) control material.  Alternatively, the real time NASBA detects hMPV viral 
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RNA from the A strain with high efficiency yet the limit of detection is not as sensitive from the 
strain B.  When comparing the two assays in patient studies, each of the diagnostic tests detected 
viral infections that failed to be detected by the other molecular based method (Table 7).  The 
NASBA could only detect 33% of the hMPV positive patients as indicated by RT-PCR in the 
CHP study.  hMPV was detected at a low prevalence in lung transplant recipients (2.14%), 
however, during the late winter months the prevalence of hMPV goes up to 9.6% indicating that 
this virus is seasonal and may play an important role as a respiratory pathogen during this time 
period.  hMPV was detected in children suspected of pertussis at an expected low level of 
prevalence (1.83%).  However, this study only includes patient specimens from September to 
January.  The peak season for hMPV is February to April.  A majority of the positives from this 
study, including the non reproducible positives were in January.  This prevalence would be 
expected to increase during these late winter months.  hMPV is a seasonal respiratory virus 
which infects children and immunosuppressed individuals and can be detected by molecular 
based methods.   
    This research is of major public health significance due to the amount of respiratory infections 
that are going undiagnosed or being treated with unnecessary antibiotics.  It is important for our 
physicians to not only know that hMPV is present in our community but also to be able to detect 
it.  This study reports the first evidence of hMPV in the Pittsburgh area and demonstrates the 
importance of this virus as a critical player among respiratory pathogens in both 
immunosuppressed lung transplant recipients and children. 
    Future work on this project includes; completing the pediatric study through the winter season 
to get an appropriate prevalence of hMPV in this patient cohort, repeating previous positives to 
determine the reproducibility of the low level positives for this assay, sequencing the positive 
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patients to determine which genetic lineages are being missed by certain molecular assays and to 
determine if there are certain strains more prevalent than others within our community, and to 
attempt to culture the patient positives by cell culture to grow up a virus stock and confirm PCR 
based positives.   
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